FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
The agency has accepted the phosphate binder resubmission after a June 2026 complete response letter that cited deficiencies at the original drug product vendor.
Unicycive Therapeutics said the US Food and Drug Administration has accepted its resubmitted new drug application for oxylanthanum carbonate, a phosphate binder intended to treat hyperphosphatemia in dialysis patients. The company reported the news alongside its third-quarter 2026 results, with a PDUFA goal date of 25 March 2027.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Unicycive Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Unicycive Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.